In particular, cancer therapy involving radiation, platinum, and topoisomerase II inhibitors shows a preference for selecting mutations in DNA damage response (DDR) genes such as TP53, PPM1D and CHEK2 (38). This evidence concerns the gene TP53 and cancer.